Biosimilar competition emerging for anti-CD20 class as Ocrevus patents expire (2027-2029 timeframe), potentially compressing pricing across the category by 30-50%
Shift toward oral disease-modifying therapies or higher-efficacy BTK inhibitors in development that could reduce infused therapy market share
Medicare drug price negotiation provisions under IRA could impact pricing power post-2029 if Briumvi becomes eligible for negotiation
Regulatory risk if safety signals emerge in post-marketing surveillance (PML, infections, infusion reactions)
Roche's Ocrevus dominance with ~$5B+ annual sales and entrenched market position across 60%+ of anti-CD20 MS market share
Novartis Kesimpta (ofatumumab) gaining share as self-administered subcutaneous option with no infusion burden
Pipeline competition from Merck's BTK inhibitor evobrutinib and other oral high-efficacy therapies in late-stage development
Limited differentiation beyond infusion time may not justify market share gains if payers favor lower-cost alternatives
Negative operating cash flow of $-0.0B (approximately breakeven) indicates limited margin for error if revenue disappoints
Debt of 0.42x equity is manageable but any need for additional capital could be dilutive given current valuation
Burn rate risk if commercial execution falters and company cannot sustain profitability, potentially requiring equity raise at unfavorable terms
StructuralCompetitiveBalance Sheet